Tourmaline Bio Stock Price, News & Analysis

Tourmaline Bio (NASDAQ: TRML) presented additional data from its Phase 2 TRANQUILITY trial of pacibekitug at the ESC Congress 2025. The trial demonstrated significant results in treating patients with elevated hs-CRP and chronic kidney disease.

The data showed consistent reductions in high-sensitivity C-reactive protein (hs-CRP) across various patient subgroups. Notably, pacibekitug achieved >85% hs-CRP reductions in the 50mg quarterly dosing arm, becoming the first IL-6 inhibitor to demonstrate such efficacy with quarterly dosing. The drug also showed statistically significant reductions in secondary biomarkers including lipoprotein(a), fibrinogen, and serum amyloid A.

Based on these positive results, Tourmaline plans to initiate a Phase 2 proof-of-concept study in abdominal aortic aneurysm (AAA) and continue preparations for a Phase 3 cardiovascular outcomes trial in ASCVD patients.

Tourmaline Bio (NASDAQ: TRML) reported Q2 2025 financial results and highlighted significant progress in its clinical programs. The company announced positive topline results from the Phase 2 TRANQUILITY trial of pacibekitug, demonstrating rapid and significant reductions in high-sensitivity C-reactive protein with quarterly dosing.

Key financial metrics include cash position of $256.4 million as of June 30, 2025, providing runway into H2 2027. Q2 2025 saw net loss of $23.1 million ($0.90 per share), with R&D expenses at $19.6 million and G&A expenses at $6.3 million.

The company plans to initiate a Phase 2 proof-of-concept trial in abdominal aortic aneurysm in H2 2025 and is preparing for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease. Additional TRANQUILITY trial data will be presented at the upcoming European Society of Cardiology Congress.

Tourmaline Bio (NASDAQ: TRML) announced positive topline results from its Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease. The trial demonstrated that all pacibekitug doses achieved rapid, deep, and durable reductions in hs-CRP through Day 90 compared to placebo (p<0.0001). Notably, the 50mg quarterly dose achieved >85% hs-CRP reductions from baseline, making pacibekitug the first IL-6 inhibitor to show such results with quarterly dosing. Safety data showed comparable adverse event rates between treatment and placebo groups. Based on these results, Tourmaline plans to advance pacibekitug into a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease and a planned Phase 2 trial in abdominal aortic aneurysm in the second half of 2025.

Tourmaline Bio (NASDAQ: TRML) announced it will host a conference call and webcast on May 20, 2025 at 8:30 a.m. ET to present topline results from its Phase 2 TRANQUILITY trial of pacibekitug. The study evaluates the drug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. The presentation will feature management alongside Dr. Deepak L. Bhatt, Director of Mount Sinai Fuster Heart Hospital and Chair of Tourmaline's Cardiovascular Scientific Advisory Board.

Tourmaline Bio (NASDAQ: TRML) reported Q1 2025 financial results and business updates. The company's Phase 2 TRANQUILITY trial for pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease is over-enrolled with 143 participants and remains on track for topline data in Q2 2025. The company ended Q1 with $275.3 million in cash, providing runway into H2 2027. Financial results showed R&D expenses of $20.3 million (up from $11.4M in Q1 2024) and a net loss of $23.0 million ($0.89 per share). The company is advancing pacibekitug for potential treatment of atherosclerotic cardiovascular disease (ASCVD) and abdominal aortic aneurysm (AAA), with plans to share additional development details alongside TRANQUILITY data. Their Phase 2b spiriTED trial for Thyroid Eye Disease continues with topline data expected in H2 2025.

Tourmaline Bio (NASDAQ: TRML) has reported its Q4 and full year 2024 financial results. The company has successfully over-enrolled its Phase 2 TRANQUILITY trial to 143 participants, with topline data expected in Q2 2025. The trial evaluates pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.

Financial highlights include a strong cash position of $294.9 million as of December 31, 2024, providing runway into H2 2027. R&D expenses increased to $67.0 million for FY2024, up from $32.4 million in 2023. Net loss widened to $73.2 million for FY2024 compared to $42.1 million in 2023.

The company strengthened its Cardiovascular Scientific Advisory Board with the appointments of several distinguished experts and continues to advance its clinical programs in cardiovascular inflammation and thyroid eye disease, with the Phase 2b spiriTED trial results expected in H2 2025.

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025.

The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 4:20 pm ET in Miami. Interested parties can access both the live webcast and replay through the 'Events and Presentations' section under News & Investors on Tourmaline Bio's website at ir.tourmalinebio.com.

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York.

The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will participate in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:30 pm ET. Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section on Tourmaline Bio's investor relations website at ir.tourmalinebio.com.

Tourmaline Bio (NASDAQ: TRML) has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board. Dr. Ridker, who serves as Eugene Braunwald Professor of Medicine at Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, brings over 30 years of expertise in cardiovascular disease research.

Dr. Ridker's contributions include developing the first FDA-approved diagnostic test for vascular inflammation (hs-CRP), demonstrating statin therapy's dual lipid-lowering and anti-inflammatory effects, and proving the inflammation hypothesis of atherothrombosis in humans. His work has led to the development of various anti-inflammatory agents targeting heart disease.

This appointment comes as Tourmaline awaits results from its Phase 2 TRANQUILITY trial and prepares for the future development of pacibekitug to reduce inflammation in cardiovascular diseases.